High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.

Y Merrouche; J M Extra; D Abigerges; R Bugat; G Catimel; E Suc; M Marty; P Hérait; M Mahjoubi; J P Armand

doi:10.1200/JCO.1997.15.3.1080

High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.

Identifier:nobleid.org/w1/20260515/DCDC5CD5

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/DCDC5CD5.svg?ark=w1%2F20260515%2FDCDC5CD5)](https://nobleid.org/work/w1/20260515/DCDC5CD5)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.

Identifier:nobleid.org/w1/20260515/DCDC5CD5

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/DCDC5CD5.svg?ark=w1%2F20260515%2FDCDC5CD5)](https://nobleid.org/work/w1/20260515/DCDC5CD5)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work